

Contents

<i>List of figures and tables</i>	ix
<i>List of contributors</i>	xi
<i>Forewords</i>	
<i>Professor Margot Jefferys</i>	xiii
<i>Professor Michael Shepherd</i>	xv
<i>Preface</i>	xvii
<i>Introduction</i>	
<i>Jonathan Gabe</i>	1

Part I The contribution of the social sciences

1 The contribution of psychology to understanding long-term tranquilliser use <i>Susan Golombok</i>	15
2 Personal troubles and public issues: the sociology of long-term tranquilliser use <i>Jonathan Gabe</i>	31
3 The culture of long-term tranquilliser users <i>Michael Montagne</i>	48
4 Long-term tranquilliser use: the contribution of epidemiology <i>Paul Williams and Cesario Bellantuono</i>	69
5 Long-term tranquilliser use: the contribution of health economics <i>Alan Shiell</i>	92

- 6 Decoding advertising: the role of communication studies in explaining the popularity of minor tranquillisers
Jane E. Prather 112

- 7 The political economy of long-term minor tranquilliser use
Larry Ray 136

Part II Evaluating the contribution of the social sciences

- 8 Long-term tranquilliser use: a general practitioner's view
John Horder 163

- 9 The benzodiazepine controversy: a psychiatrist's reaction
Anthony Clare 180

- 10 Long-term tranquilliser use: a health policy perspective
Helene L. Lipton and Lisa A. Bero 190

Name index 204

Subject index 209

Figures and tables

Table 3.1	Images and metaphors of tranquillisers and tranquilliser use	54
Table 4.1	The uses of epidemiology and their relevance to long-term tranquilliser use	71
Table 4.2	The extent of long-term tranquilliser use	73
Table 4.3	Activities for which respondents expressed a need for tranquillisers	77
Table 4.4	Findings related to dependence on tranquillisers	78
Table 4.5	Frequency of benzodiazepine withdrawal phenomena reported in six studies	79
Table 4.6	Surveys of psychotropic prescription and consumption	81
Table 4.7	Tranquilliser consumption in Italy	82
Figure 4.1	Survival distributions of duration of psychotropic drug use	83
Table 4.8	Probability of discontinuing psychotropic drug treatment within the next two weeks	85
Figure 4.2	Survival distributions of duration of psychotropic drug use in patients of six general practitioners: between doctor differences	85
Table 5.1	Prescriptions for minor tranquillisers (millions)	93
Table 5.2	Hypothetical evaluation of alternative methods of managing minor affective disorders	96
Table 5.3	Evaluation of alternatives to conventional management of patients with minor affective disorders	99
Table 7.1	Number of prescriptions for seven leading benzodiazepines, UK, 1976-86 (in millions)	141
Table 7.2	Share of UK prescriptions of seven leading benzodiazepines, 1972-85	142

x *Figures and tables*

Table 7.3	Prices of Librium and Valium (100 tablets), 1975 in USD, wholesale	146
Table 7.4	Adverse reports, benzodiazepines, UK, 1978–87	151
Table 8.1	Comparison of outcome studies, as determined by ‘caseness’	169